Cardiac Effects of Pulmonary Disease

Veterinary Clinics of North America - Small Animal Practice

Volumn 37, Issue 5, 2007, Pages 949-962

  Campbell, Fiona E ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; NITRIC OXIDE; OXYGEN; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; SILDENAFIL; TADALAFIL; VASODILATOR AGENT;

CONTINUOUS INFUSION; COR PULMONALE; DOG DISEASE; DOPPLER ECHOCARDIOGRAPHY; DRUG HALF LIFE; ENDOTHELIAL DYSFUNCTION; EXERCISE TOLERANCE; HEART AUSCULTATION; HEART CATHETERIZATION; HEART RIGHT VENTRICLE HYPERTROPHY; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE OVERLOAD; HYPERPNEA; HYPOXIA; LUNG COMPLIANCE; LUNG DISEASE; LUNG TRANSPLANTATION; NONHUMAN; OXYGEN THERAPY; PATHOPHYSIOLOGY; PHYSICAL EXAMINATION; PROGNOSIS; PULMONARY HYPERTENSION; RESPIRATORY DISTRESS; REVIEW; SYNCOPE; TACHYPNEA; THORAX RADIOGRAPHY; VASCULAR RESISTANCE; VASOCONSTRICTION;

ANIMALS; CAT DISEASES; CATS; DIAGNOSIS, DIFFERENTIAL; DOG DISEASES; DOGS; ECHOCARDIOGRAPHY, DOPPLER; HYPERTENSION, PULMONARY; LUNG DISEASES; PROGNOSIS;

SYNCOPE;

EID: 34547680473     PISSN: 01955616     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cvsm.2007.05.006     Document Type: Review

References (62)

1. Estaves I., Tessier D., Dandrieux J., et al. Reversible pulmonary hypertension presenting simultaneously with an atrial septal defect and angiostrongylosis in a dog. J Small Anim Pract 45 4 (2004) 206-209
2. Glaus T.M., Soldati G., Maurer R., et al. Clinical and pathological characterisation of primary pulmonary hypertension in a dog. Vet Rec 154 (2004) 786-789
3. Kolm U.S., Amberger C.N., Boujon C.E., et al. Plexogenic pulmonary arteriopathy in a Pembroke Welsh corgi. J Small Anim Pract 45 (2004) 461-466
4. Nicolle A.P., Chetboul V., Tessier-Vetzel D., et al. Severe pulmonary arterial hypertension due to Angiostrongylus vasorum in a dog. Can Vet J 47 8 (2006) 792-795
5. Pyle R.L., Abbott J.A., and MacLean H.N. Severe pulmonary hypertension and cardiovascular sequelae in dogs. Vet Med 99 6 (2004) 530-541
6. Pyle R.L., King M.D., Saunders G.K., et al. Pulmonary thrombosis due to idiopathic main pulmonary artery disease. Vet Med 99 10 (2004) 836-842
7. Serres F., Nicolle A.P., Tissier R., et al. Efficacy of oral tadalafil, a new long-acting phosphodiesterase-5 inhibitor, for short-term treatment of pulmonary arterial hypertension in a dog. J Vet Med A Physiol Pathol Clin Med 53 3 (2006) 129-133
8. Johnson L.R., Boon J.A., and Orton E.C. Clinical characteristics of 53 dogs with Doppler-derived evidence of pulmonary hypertension: 1992-1996. J Vet Intern Med 13 (1999) 440-447
9. Bach J.F., Rozanski E.A., MacGregor J., et al. Retrospective evaluation of sildenafil citrate as a therapy for pulmonary hypertension in dogs. J Vet Intern Med 20 (2006) 1132-1135
10. Brewster R.D., Benjamin S.A., and Thomassen R.W. Spontaneous cor pulmonale in laboratory beagles. Lab Anim Sci 33 3 (1983) 299-302
11. McLaughlin V.V., and Rich S. Cor pulmonale. In: Baunwald E., Zipes D.P., and Libby P. (Eds). Heart disease: a textbook of cardiovascular medicine. 6th edition (2001), WB Saunders, Philadelphia 1936-1954
12. Schober K.E., and Baade H. Doppler echocardiographic prediction of pulmonary hypertension in West Highland White Terriers with chronic pulmonary disease. J Vet Intern Med 20 (2006) 912-920
13. Voelkel N.F., and Tuder R.M. Cellular and molecular mechanisms in the pathogenesis of pulmonary hypertension. Eur Respir J 8 (1995) 2129-2138
14. Pietra G.G., Capron F., Stewart S., et al. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 43 (2004) 25S-32S
15. Perry L.A., Dillon A.R., and Bowers T. Pulmonary hypertension. The Compendium on Continuing Education for the Practicing Veterinarian 13 2 (1991) 226-232
16. Kittleson M.D., and Kienle R.D. Patent ductus arteriosus. In: Kittleson M.D., and Kienle R.D. (Eds). Small animal cardiovascular medicine (1998), Mosby, New York 218-230
17. Pirofsky B. The determination of blood viscosity in man by a method based on Poiseuille's law. J Clin Invest 32 (1953) 292-298
18. Ganong W.F. Pulmonary function. In: Foltin J., Mattagrano M., Ranson J., et al. (Eds). Review of medical physiology (1995), Appleton and Lange, East Norwalk (CT) 591-607
19. Wauthy P., Pagnamenta A., Vassalli F., et al. Right ventricular adaptation to pulmonary hypertension: an interspecies comparison. Am J Physiol Heart Circ Physiol 286 4 (2004) H1441-H1447
20. Glaus T.M., Hassig M., Baumgartner C., et al. Pulmonary hypertension induced in dogs by hypoxia at different high-altitude levels. Vet Res Commun 27 (2003) 661-670
21. Budhiraja R., Tuder R.M., and Hassoun P.M. Endothelial dysfunction in pulmonary hypertension. Circulation 109 (2004) 159-165
22. Channick R.N., Sitbon O., Barst R.J., et al. Endothelin receptor antagonists in pulmonary arterial hypertension. J Am Coll Cardiol 43 12 (2004) 62S-67S
23. Channick R.N., Simonneau G., Sitbon O., et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358 (2001) 1119-1123
24. Rubin L.J., Badesch D., Barst R.J., et al. Bosentan therapy for pulmonary arterial hypertension. N Eng J Med 346 (2002) 896-903
25. Archer S., and Rich S. Primary pulmonary hypertension. Circulation 102 (2000) 2781-2791
26. Eickelberg O., Yeager M.E., and Grimminger F. The tantalizing triplet of pulmonary hypertension-BMP receptors, serotonin receptors and angiopoietins. Circ Res 60 (2003) 465-467
27. Barst R.J., McGoon M.D., Torbicki A., et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 43 12 (2004) 40S-47S
28. Hoeper M.M., Oudiz R.J., Peacock A., et al. End points and clinical trial designs in pulmonary arterial hypertension. J Am Coll Cardiol 43 12 (2004) 48S-55S
29. Zucker I.H., and Cornish K.G. The Bezold-Jarisch reflex in the conscious dog. Circ Res 49 (1981) 940-948
30. Nelson G.S., Sayed-Ahmed E.Y., Kroeker C.A., et al. Compression of interventricular septum during right ventricular pressure loading. Am J Physiol Heart Circ Physiol 280 6 (2001) H2639-H2648
31. Gaynor S.L., Maniar H.S., Bloch J.B., et al. Right atrial and ventricular adaptation to chronic right ventricular pressure overload. Circulation 112 9 (2005) I212-I218
32. Kittleson M.D. Signalment, history and physical examination. In: Kittleson M.D., and Kienle R.D. (Eds). Small animal cardiovascular medicine (1998), Mosby, New York 36-46
33. Thrall D.E. Textbook of veterinary diagnostic radiology. 3rd edition (1998), Saunders, Philadelphia
34. Boon J.A. Manual of veterinary echocardiography (1998), Williams and Wilkins, Baltimore (MD)
35. Glaus T.M., Hauser K., Hassig M., et al. Non-invasive measurement of the cardiovascular effects of chronic hypoxaemia on dogs living at moderately high altitude. Vet Rec 152 (2003) 800-803
36. Uehara Y. An attempt to estimate the pulmonary artery pressure in dogs by means of pulsed Doppler echocardiography. J Vet Med Sci 55 (1993) 307-312
37. Glaus T.M., Tomsa K., Hassig M., et al. Echocardiographic changes induced by moderate to marked hypobaric hypoxia in dogs. Vet Radiol Ultrasound 45 3 (2004) 233-237
38. Johnson L.R., Michael M.R., and Baker D.C. Pulmonary thromboembolism in 29 dogs: 1985-1995. J Vet Intern Med 13 (1999) 338-345
39. Currie P.J., Seward J.B., Chan K.L., et al. Continuous wave Doppler determination of right ventricular pressure: a simultaneous Doppler-catheterization study in 127 patients. J Am Coll Cardiol 6 (1985) 750-756
40. Gross D.R. Normal cardiovascular parameters from intact, awake animals. In: Gross D.R. (Ed). Animal models in cardiovascular research (1994), Kluwer, Boston 343-395
41. McQuillan B.M., Picard M.H., Leavitt M., et al. Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects. Circulation 104 (2001) 2797-2802
42. Ahearn G.S., Tapson V.F., Rebeiz A., et al. Electrocardiography to define clinical status in primary pulmonary hypertension and pulmonary arterial hypertension secondary to collagen vascular disease. Chest 122 (2002) 524-527
43. Dunbar I. Diagnosis and treatment of severe pediatric pulmonary hypertension. Cardiol Rev 9 4 (2001) 227-236
44. Barst R.J., Rubin L.J., and Long W.A. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 30 334 (1996) 296-302
45. Higenbottam T., Wells F., Wheeldon D., et al. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet 1 (1984) 1046-1047
46. Rich S., Kaufmann E., and Levy P.S. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Eng J Med 327 (1992) 76-81
47. Fuster V., Steele P.M., Edwards W.D., et al. Primary pulmonary hypertension: natural history and importance of thrombosis. Circulation 70 (1984) 580-587
48. Ivy D.D., Parker D., Doran A., et al. Acute hemodynamic effects and home therapy using a novel pulsed nasal nitric oxide delivery system in children and young adults with pulmonary hypertension. Am J Cardiol 92 (2003) 886-890
49. Badesch D., McLaughlin V.V., Delcroix M., et al. Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol 43 12 (2004) 56S-61S
50. Mikhail G., Gibbs J.S.R., Richardson M., et al. An evaluation of nebulized prostacyclin in patients with primary and secondary pulmonary hypertension. Eur Heart J 18 (1997) 1499-1504
51. Olschewski H., Simonneau G., Galie N., et al. Inhaled iloprost for severe pulmonary hypertension. N Eng J Med 347 (2002) 322-329
52. Klepetko W., Mayer E., Sandoval J., et al. Interventional and surgical modalities of treatment for pulmonary arterial hypertension. J Am Coll Cardiol 43 12 (2004) 73S-80S
53. Ghofrani H.A., Pepki-Zaba J., Barbera J.A., et al. Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. J Am Coll Cardiol 43 12 (2004) 68S-72S
54. Wright P.J. Comparison of phosphodiesterase type 5 inhibitors. Int J Clin Pract 60 8 (2006) 967-975
55. Galie N., Ghorani H.A., Torbicki A., et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Eng J Med 352 20 (2005) 2148-2157
56. Humpl T., Reyes J.T., Holtby H., et al. Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension. Circulation 111 (2005) 3274-3280
57. Mitani Y., Zaidi S.H., Dufourcq P., et al. Nitric oxide reduces vascular smooth muscle cell elastase activity through cGMP-mediated suppression of ERK phosphorylation and AML1B nuclear partitioning. FASEB J 14 (2000) 805-814
58. Nagy O., Hagnal A., Parratt J.R., et al. Sildenafil reduces arrhythmia severity during ischemia 24 h after oral administration in dogs. Br J Pharmacol 141 4 (2004) 549-551
59. Toward T.J., Smith N., and Broadley K.J. Effect of phosphodiesterase-5 inhibitor, sildenafil, in animal models of airway disease. Am J Respir Crit Care Med 169 2 (2004) 227-234
60. Sastry B.K., Narasimhan C., Reddy N.K., et al. Clinical efficacy of sildenafil in primary pulmonary hypertension. J Am Coll Cardiol 43 (2004) 1149-1153
61. Hubloue I., Rondelet B., Kerbaul F., et al. Endogenous angiotensin II in the regulation of hypoxic pulmonary vasoconstriction in anesthetized dogs. Crit Care 8 4 (2004) R163-R171
62. Buoro I.B.J., and Atwell R.B. Plasma levels of renin and aldosterone in right-sided congestive heart failure due to canine dirofilariasis. Canine Pract 17 3 (1992) 21-24